Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) , also known as B cell maturation antigen ( BCMA ) or CD269 antigen, is one of the members of the tumor necrosis factor receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and is involved in B cell development and autoimmune response. This receptor has been shown to specifically bind to tumor necrosis factor (ligand) superfamily member 13B (TNFSF13B/BAFF) , and cause NF-kappaB and MAPK8/JNK activation. BCMA also binds to different members of the TRAF family to mediate the transmission of cell survival and proliferation signals, so it can be used as a molecular target for drug development for certain immunodeficiency or autoimmune diseases. In BCMA as a target CAR-T has been in clinical trials for multiple myeloma. This product is a second-generation CAR lentiviral expression plasmid targeting BCMA.

Product name: Lenti-EF1a-BCMA-2nd-CAR

Promoter: EF1a ^[1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp

Tag: EGFRt ^[2]

Remarks:

1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2.  EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells . At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only be used as CAR-T screening markers, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB006A )